These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30559264)

  • 1. New therapies for hemophilia.
    Weyand AC; Pipe SW
    Blood; 2019 Jan; 133(5):389-398. PubMed ID: 30559264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
    Trinchero A; Sholzberg M; Matino D
    Hamostaseologie; 2020 Aug; 40(3):311-321. PubMed ID: 32726826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
    Mancuso ME; Mahlangu JN; Pipe SW
    Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapies using nonfactor products for patients with hemophilia and inhibitors.
    Nogami K; Shima M
    Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
    Monahan PE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in developing specific therapies for haemophilia.
    Ling G; Nathwani AC; Tuddenham EGD
    Br J Haematol; 2018 Apr; 181(2):161-172. PubMed ID: 29359795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving Complexity in Hemophilia Management.
    Croteau SE
    Pediatr Clin North Am; 2018 Jun; 65(3):407-425. PubMed ID: 29803274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Molecular Revolution in the Treatment of Hemophilia.
    Butterfield JSS; Hege KM; Herzog RW; Kaczmarek R
    Mol Ther; 2020 Apr; 28(4):997-1015. PubMed ID: 31843450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic treatment in hemophilic patients with inhibitors.
    Haya S
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S14-S18. PubMed ID: 31517711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Congenital hemophilia: a new treatment paradigm].
    Shima M
    Rinsho Ketsueki; 2019; 60(6):647-658. PubMed ID: 31281158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia in a Changing Treatment Landscape.
    Pelland-Marcotte MC; Carcao MD
    Hematol Oncol Clin North Am; 2019 Jun; 33(3):409-423. PubMed ID: 31030810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 16. The past and future of haemophilia: diagnosis, treatments, and its complications.
    Peyvandi F; Garagiola I; Young G
    Lancet; 2016 Jul; 388(10040):187-97. PubMed ID: 26897598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions.
    Levy-Mendelovich S; Livnat T; Barg AA; Kidon M; Brutman-Barazani T; Kenet G
    Blood Cells Mol Dis; 2020 Feb; 80():102370. PubMed ID: 31669933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Therapeutic Strategies in the Treatment of Hemophilia A.
    Muczynski V; Christophe OD; Denis CV; Lenting PJ
    Semin Thromb Hemost; 2017 Sep; 43(6):581-590. PubMed ID: 28750425
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.